


# WebEx Tools for Interacting with Presenters Will Be in Use During this Meeting

- **Recording meeting for future reference**
- Large number of meeting participants requires system for orderly interaction
  - Will use WebEx tools
- To make a comment and/or ask a question during the presentation period:
  - Submit in text by using the Chat window (purple outline) and addressing message to 'Questions Here'
- More in-depth Q&A period planned for end of meeting





# DILIsym® v3A User Training

April 17, 2014

Speakers: Brett A. Howell, Scott Q. Siler





Contact: [bhowell@thehamner.org](mailto:bhowell@thehamner.org), [silerconsulting@comcast.net](mailto:silerconsulting@comcast.net)

Please note: this presentation,  
including questions from the  
audience, is being recorded


Please send questions to the  
DILIsym® team through the individual  
listed as "Questions Here" (chat) so  
we can read them aloud and answer  
them, time permitting



# The DILI-sim Team and the SAB




# 2014 DILI-sim Initiative Key Dates



# The DILIsym.com Website

- [www.DILIsym.com](http://www.DILIsym.com):
  - Stand-alone webpage, linked to the Hamner Institutes webpage, that provides information and file access
  - Online forum for virtual discussions through threads and post between member companies, the modeling team, and the SAB
    - Password protected
    - Allows for model access via the web
    - General scientific discussions
    - DILI-sim Initiative related discussions (operations)
    - DILIsym® model design discussions
    - DILIsym® technical/practical discussions related to use
    - Additional means for tech support for model users
  - DILIsym® files and documentation are available via a password protected site
- DILI-sim members register for an account to access files and forum discussions
  - Click 'Register' at the top right-hand corner of the homepage



# DILIsym® v3A Training Session Goals

- This training session will provide users with knowledge of updates and additions to DILIsym® as of the v3A release
- This training session should be a supplement to previously recorded training sessions
  - DILIsym® versions 1A through 2C training sessions
  - All sessions accessible at [www.DILIsym.com](http://www.DILIsym.com)
- This training session is not an in-depth exploration of the application of the model, but application questions are welcome at the end of the session

# DILIsym<sup>®</sup> v3A User Training Agenda

The Items Below will be Discussed with Slides and Live MATLAB Demo


- Overview of DILIsym<sup>®</sup> v3A and MATLAB directory structure
- Mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
- New population samples (SimPops<sup>™</sup>) included combining the effects of bile acids and direct mitochondrial dysfunction
- New feature for automatic system pre-simulation equilibration for the mitochondrial dysfunction and bile acid representations due to oscillatory behaviors
- PBPK framework expansion in v3A
- Graphical user interface enhancements
- Code format parameter file changes






# DILIsym<sup>®</sup> v3A Overview

- **Multiple species: human, rat, mouse, and dog**
  - Population variability
- **The three primary acinar zones of liver represented**
- **Essential cellular processes represented to multiple scales in interacting sub-models**
  - Pharmacokinetics
  - Dosing (IP, IV, Oral)
  - Transporter Inhibition
  - Drug metabolism
  - GSH depletion
  - Injury progression
  - Mitochondrial dysfunction, toxicity
  - Bile acid mediated toxicity
  - Cellular energy balance
  - Hepatocyte life cycle
  - Macrophage, LSEC life cycles
  - Immune mediators
  - Caloric intake
  - Biomarkers



## • Hepatotoxicity exemplars

- Reactive metabolite mediated
  - Acetaminophen
  - Methapyrilene
  - Furosemide
  - Aflatoxin B1
  - Carbon tetrachloride
- Mitochondrial dysfunction
  - Etomoxir
  - Buprenorphine
  - Tolcapone
  - CP-724714
- Bile acid transporter inhibition
  - Glibenclamide
  - CP-724714
  - Bosentan
  - Telmisartan
  - Tolcapone
  - Troglitazone
- Single, multiple dose protocols
- Single, combination drug protocols




## • Compartment-based modeling

- >500 state variables
- 'Form to function' connection
- Ordinary differential equations
- Code or GUI functionality



# Highlights of DILIsym<sup>®</sup> v3A

- Added option of mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
- Expanded and refined the representation of innate immune contributions to injury and recovery
  - Mediator production structure altered
  - Innate immune parameter values for mouse, rat, dog, and human updated
- Introduced new structure for pre-equilibration of state variables prior to simulations
- Expanded capabilities of GUI interface
- Expanded PBPK framework




- Introduced additional exemplar compounds for exposure-related toxicity
  - Tolcapone
  - Telmisartan
  - Bosentan
  - Carbon tetrachloride
- Additional SimPops<sup>™</sup>, capturing impact of variability in key pathways

# Expanded Capabilities and Changes for DILIsym<sup>®</sup> v3A



- PBPK framework expanded for additional drug metabolism schemes
  - Secondary metabolite generation now possible
  - Suicide inhibition now possible
  - Drug metabolism enzyme induction added
  - Free drug concentration representation also adjusted
- Innate immune representation expanded and enhanced
  - Mediator production structure altered
  - Innate immune parameter values for mouse, rat, dog, and human updated
- Added option of mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
- Added new feature for automatic system pre-simulation equilibration for the mitochondrial dysfunction and bile acid representations due to oscillatory behaviors
- New population samples (SimPops<sup>™</sup>) included combining the effects of bile acids and direct mitochondrial dysfunction
  - NASH-like patients with severely compromised mitochondrial function are also included
- New drug/chemical representations for:
  - Telmisartan
  - Carbon tetrachloride
  - Bosentan
  - Tolcapone
- Numerous graphical user interface (GUI) enhancements, including:
  - Parameter names and descriptions are now visible from within the GUI
  - New plotting feature allowing comparisons to data within GUI plot window
  - New Data comparisons feature allowing storage of population sample (SimPops) simulations, and comparisons to measured data
- Expanded Zotero reference database (contact us for real-time access)



# DILIsym<sup>®</sup> v3A User Training Agenda

The Items Below will be Discussed with Slides and Live MATLAB Demo


- Overview of DILIsym<sup>®</sup> v3A and MATLAB directory structure
- Mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
- New population samples (SimPops<sup>™</sup>) included combining the effects of bile acids and direct mitochondrial dysfunction
- New feature for automatic system pre-simulation equilibration for the mitochondrial dysfunction and bile acid representations due to oscillatory behaviors
- PBPK framework expansion in v3A
- Graphical user interface enhancements
- Code format parameter file changes







# Liver Bile Acids Elicit ATP Reductions in More Mechanistic Manner in DILIsym<sup>®</sup> v3A

- Liver bile acids cause reductions in mitochondria proton gradient in v3A
  - BA H<sup>+</sup> Gradient Uncoupling
- Parameter optimization based on Yang et al. hepatocyte studies (*submitted*)
  - Measured ATP and cell death following exposure to different levels of bile acids
  - Supported by DILI-sim Initiative
- Prior representation still available as an option
  - Direct effect on ATP synthesis
- BA H<sup>+</sup> Gradient Uncoupling is better option if combined with other mitochondria mechanisms
  - Includes integration of mitochondria feedback signals
  - BA ATP Inhibition useful when it is the only mechanism



# Summary of Findings from Sandwich Culture Hepatocyte Bile Acid Toxicity Studies

- Human SCH were more resistant to LCA-mediated toxicity compared to rat SCH based on the intracellular LCA concentrations
- CDCA induced medium-concentration dependent ATP loss and toxicity in rat and human SCH. Toxicity was correlated with hepatic unconjugated CDCA in rat SCH
  - Various bile acid species have been reported to initiate MPT, decrease mitochondria proton gradient, and decrease OCR<sup>‡</sup>
- Both BA H<sup>+</sup> Gradient Uncoupling and BA ATP Inhibition options are optimized based on these data



<sup>‡</sup> Denk 2012, Sokol 2005, Botla 1995, Rolo 2003, Rolo 2004, Utanohara 2005, Yerushalmi 2001, Nadanaciva unpublished

Yang unpublished

# Three Parameters Required to Activate BA H+ Gradient Uncoupling

The screenshot displays the DILIsym v3A software interface with several windows open. The 'SimSingle Setup File' window shows 'Parameters\_Human\_Tolcapone\_v3A' selected for 'Drug Parameters'. The 'Drug Parameter Values-P...' window lists parameters for 'Mechanism selection', 'Drug toxicity parameters', and 'Mechanistic interventions'. The 'Drug toxicity parameters-Parameters\_Hum...' window shows a table of parameters with values and units. The 'Mechanistic interventions-Parameters\_Hu...' window shows a table of parameters with values and units. The 'Mechanism selection-Parameters\_Human\_Tolcapone\_v3A' window shows a table of species and their associated parameters, with checkboxes for 'RNS-ROS production', 'ATP utilization', 'Direct necrosis', 'BSEP/NTCP inhib', 'Proximate ox inhib', 'Fatty acid ox inhib', 'ETC inhib', 'Mito ATP synth inhib', 'Mito uncoupler 1', 'Mito uncoupler 2', and 'MPT initiation'.

**Drug toxicity parameters-Parameters\_Hum...**

Parameter	Value	Units
RNS_ROS_prod_const	5000	mL/mol/hour
Hill_direct_necrosis	1	dimensionless
Vmax_direct_necrosis	1	dimensionless
Km_direct_necrosis	1.0000e-06	dimensionless
ATP_util_Vmax	6	1/hour
ATP_util_Km	1.5000e-07	mol/mL
ATP_util_Hill	1.6000	dimensionless
MitoS_ETC_Inhib	3.5000e-08	mol/mL
MitoS_ATP_Inhib	1	mol/mL
MitoS_FA_Ox_Inhib	1	mol/mL

**Mechanistic interventions-Parameters\_Hu...**

Parameter	Value	Units
Mac_depletion_switch	0	dimensionless
Mac_depletion_time_start	2	hour
Mac_depletion_time_stop	50	hour
Mac_depletion_fraction	0.9500	dimensionless
Anti_HMGB1_switch	0	dimensionless
Anti_HMGB1_time_start	0	hour
Anti_HMGB1_time_stop	168	hour
Anti_HMGB1_effect_level	0.0500	dimensionless
Anti_HMGB1_switch	0	dimensionless

**Mechanism selection-Parameters\_Human\_Tolcapone\_v3A**

Species	RNS-ROS production	ATP utilization	Direct necrosis	BSEP/NTCP inhib	Proximate ox inhib	Fatty acid ox inhib	ETC inhib	Mito ATP synth inhib	Mito uncoupler 1	Mito uncoupler 2	MPT initiation
Compound W	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound W metabolite A	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound W metabolite B	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound W reactive metabolite 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound W RM 1 protein adducts	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound W reactive metabolite 2	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound W RM 2 protein adducts	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound X	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound X metabolite A	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound X metabolite B	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound X reactive metabolite 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound X RM 1 protein adducts	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound X reactive metabolite 2	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound X RM 2 protein adducts	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Compound Y	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



# DILIsym<sup>®</sup> v3A User Training Agenda

The Items Below will be Discussed with Slides and Live MATLAB Demo

- Overview of DILIsym<sup>®</sup> v3A and MATLAB directory structure
- Mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
- New population samples (SimPops<sup>™</sup>) included combining the effects of bile acids and direct mitochondrial dysfunction
- New feature for automatic system pre-simulation equilibration for the mitochondrial dysfunction and bile acid representations due to oscillatory behaviors
- PBPK framework expansion in v3A
- Graphical user interface enhancements
- Code format parameter file changes




# New Mitochondria and Bile Acids SimPops™ Introduced in DILIsym® v3A

SimPops™	Species/ Strain	Population Sample Size	Number of Parameters Varied	Applicable Hepatotoxicity Mechanisms
Mouse_ROS_v2A_1	Mice	400	10	Reactive oxygen species
Mouse_mito_v3A_5_exploration_only	Mice	200	5	Mitochondria
Rat_ROS_v2A_2	Rats	400	9	Reactive oxygen species
Rat_mito_v3A_4_exploration_only	Rats	200	5	Mitochondria
Rat_bile_acid_v2B_5	Rats	191	11	Bile Acids
Dog_ROS_v2A_3	Dogs	338	12	Reactive oxygen species
Dog_mito_v3A_3_exploration_only	Dogs	200	6	Mitochondria
Human_ROS_v2A_4	Humans	458	9	Reactive oxygen species
Human_bile_acid_v2A_5	Humans	331	10	Bile acids
Human_mito_v3A_1_exploration_only	Humans	150	2	Mitochondria
Human_mito_v3A_2_exploration_only	Humans	176	6	Mitochondria
<i>Human_mito_BA_v3A_6_exploration_only</i>	<i>Humans</i>	<i>229</i>	<i>15</i>	<i>Mitochondria and bile acids</i>

# New Exploratory SimPops™ in DILIsym® v3A (v3A\_6, N – 229) can be Used for Mitochondrial Dysfunction and/or Bile Acid Disruption

- Useful for mitochondrial dysfunction simulations
- Useful for bile acid homeostasis disruption simulations
- Useful (and designed for) combinations of bile acid homeostasis disruption and mitochondrial dysfunction
- As with other mitochondrial dysfunction SimPops™, the population sample has not been validated with endpoint patient data due to lack of available data





# DILIsym<sup>®</sup> v3A User Training Agenda

The Items Below will be Discussed with Slides and Live MATLAB Demo

- Overview of DILIsym<sup>®</sup> v3A and MATLAB directory structure
  - Mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
  - New population samples (SimPops<sup>™</sup>) included combining the effects of bile acids and direct mitochondrial dysfunction
- New feature for automatic system pre-simulation equilibration for the mitochondrial dysfunction and bile acid representations due to oscillatory behaviors
- PBPK framework expansion in v3A
  - Graphical user interface enhancements
  - Code format parameter file changes




# Automated Equilibration Simulations Have been Incorporated into DILIsym® as of v3A


- What are equilibration capabilities?
  - Equilibration is the process of running a simulation within DILIsym® (typically without drug) prior to running the simulation specified by the user (a 'pre-simulation')
- What is accomplished with equilibration?
  - Equilibration allows DILIsym® outputs (state variables and algebraic expressions) to reach new steady state values that are different than the initial starting values, due to the oscillatory nature of many aspects of DILIsym®, including meals, and due to the difficulty in calculating the correct steady state values for every output *a priori* with a large equation set
  - Loading stored steady state values is also an option in v3A
- What types of applications is equilibration recommended for?
  - Bile acid homeostasis simulations
  - Mitochondrial dysfunction simulations

# A Chronological View of Equilibration in DILIsym®


## Running an equilibration simulation



## Loading equilibrated initial conditions (default)



# DILIsym<sup>®</sup> v3A Equilibration Decision Tree



# DILIsym<sup>®</sup> v3A User Training Agenda


The Items Below will be Discussed with Slides and Live MATLAB Demo

- Overview of DILIsym<sup>®</sup> v3A and MATLAB directory structure
  - Mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
  - New population samples (SimPops<sup>™</sup>) included combining the effects of bile acids and direct mitochondrial dysfunction
  - New feature for automatic system pre-simulation equilibration for the mitochondrial dysfunction and bile acid representations due to oscillatory behaviors
- PBPK framework expansion in v3A
- Graphical user interface enhancements
  - Code format parameter file changes





# DILIsym<sup>®</sup> Metabolism Structure Changed to Accommodate Lapatinib and CCl<sub>4</sub>



- Metabolism of Met A to RM1
- Suicide inhibition of Met A -> RM1
  - Inhibition constant model
- Suicide inhibition of parent -> RM1
  - Empirical model

# Using the New Metabolism and Suicide Inhibition Parameters

- Vmax and Km defining metabolism of Metabolite A to RM1 are located in the RM1 PBPK section (applies to Compounds W and X)
  - Vmax\_CompW\_RM1\_from\_MetA (mol/h/kg<sup>0.75</sup>)
  - Km\_CompW\_RM1\_from\_MetA (mol/mL)
- Suicide inhibition parameters for parent to RM1 reaction are located in the RM1 PBPK section
  - CompW\_RM1\_inhib\_start\_time (h)
  - CompW\_RM1\_inhib\_stop\_time (h)
  - CompW\_RM1\_inhib\_percent (dimensionless)
- Suicide inhibition parameters for Metabolite A to RM1 reaction also located in the RM1 PBPK section
  - CompW\_MetA\_RM1\_inhib\_Vmax (mol/h/kg<sup>0.75</sup>)
  - CompW\_MetA\_RM1\_inhib\_Ki (mol/mL)
  - k\_enzyme\_turnover\_CompW (1/h)

# DILIsym<sup>®</sup> v3A User Training Agenda

The Items Below will be Discussed with Slides and Live MATLAB Demo

- Overview of DILIsym<sup>®</sup> v3A and MATLAB directory structure
  - Mechanistic representation of bile acid-mediated hepatocellular necrosis via bile acid induced mitochondrial dysfunction
  - New population samples (SimPops<sup>™</sup>) included combining the effects of bile acids and direct mitochondrial dysfunction
  - New feature for automatic system pre-simulation equilibration for the mitochondrial dysfunction and bile acid representations due to oscillatory behaviors
  - PBPK framework expansion in v3A
- Graphical user interface enhancements
  - Code format parameter file changes



# 2014 DILI-sim Initiative Key Dates

